Postinjektionssyndrom efter behandling med olanzapin depot

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Postinjektionssyndrom efter behandling med olanzapin depot. / Mohammad, Milan; Alaoui-Ismaili, Zakaria; Baandrup, Lone; Barzanji, Ayob Farouk.

In: Ugeskrift for Laeger, Vol. 185, No. 19, V02230069, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mohammad, M, Alaoui-Ismaili, Z, Baandrup, L & Barzanji, AF 2023, 'Postinjektionssyndrom efter behandling med olanzapin depot', Ugeskrift for Laeger, vol. 185, no. 19, V02230069. <https://ugeskriftet.dk/videnskab/postinjektionssyndrom-efter-behandling-med-olanzapin-depot>

APA

Mohammad, M., Alaoui-Ismaili, Z., Baandrup, L., & Barzanji, A. F. (2023). Postinjektionssyndrom efter behandling med olanzapin depot. Ugeskrift for Laeger, 185(19), [V02230069]. https://ugeskriftet.dk/videnskab/postinjektionssyndrom-efter-behandling-med-olanzapin-depot

Vancouver

Mohammad M, Alaoui-Ismaili Z, Baandrup L, Barzanji AF. Postinjektionssyndrom efter behandling med olanzapin depot. Ugeskrift for Laeger. 2023;185(19). V02230069.

Author

Mohammad, Milan ; Alaoui-Ismaili, Zakaria ; Baandrup, Lone ; Barzanji, Ayob Farouk. / Postinjektionssyndrom efter behandling med olanzapin depot. In: Ugeskrift for Laeger. 2023 ; Vol. 185, No. 19.

Bibtex

@article{e8d49f9f4e7a4c779d904f2f7daa0608,
title = "Postinjektionssyndrom efter behandling med olanzapin depot",
abstract = "Treatment with olanzapine depot is associated with a rare but potentially adverse reaction, namely post-injection delirium/sedation syndrome (PDSS), characterized by delirium and/or sedation. This is a case report of a 38-year-old male patient who developed symptoms consistent with PDSS shortly after receiving intramuscular injection of olanzapine depot. Clinicians should be aware of PDSS and observe patients for three hours after receiving the injection, measuring vitals and referring to medical care if necessary.",
keywords = "Male, Humans, Adult, Olanzapine/adverse effects, Antipsychotic Agents/adverse effects, Benzodiazepines/adverse effects, Schizophrenia/drug therapy, Delayed-Action Preparations/adverse effects, Syndrome, Delirium/chemically induced, Injections, Intramuscular",
author = "Milan Mohammad and Zakaria Alaoui-Ismaili and Lone Baandrup and Barzanji, {Ayob Farouk}",
year = "2023",
language = "Dansk",
volume = "185",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "19",

}

RIS

TY - JOUR

T1 - Postinjektionssyndrom efter behandling med olanzapin depot

AU - Mohammad, Milan

AU - Alaoui-Ismaili, Zakaria

AU - Baandrup, Lone

AU - Barzanji, Ayob Farouk

PY - 2023

Y1 - 2023

N2 - Treatment with olanzapine depot is associated with a rare but potentially adverse reaction, namely post-injection delirium/sedation syndrome (PDSS), characterized by delirium and/or sedation. This is a case report of a 38-year-old male patient who developed symptoms consistent with PDSS shortly after receiving intramuscular injection of olanzapine depot. Clinicians should be aware of PDSS and observe patients for three hours after receiving the injection, measuring vitals and referring to medical care if necessary.

AB - Treatment with olanzapine depot is associated with a rare but potentially adverse reaction, namely post-injection delirium/sedation syndrome (PDSS), characterized by delirium and/or sedation. This is a case report of a 38-year-old male patient who developed symptoms consistent with PDSS shortly after receiving intramuscular injection of olanzapine depot. Clinicians should be aware of PDSS and observe patients for three hours after receiving the injection, measuring vitals and referring to medical care if necessary.

KW - Male

KW - Humans

KW - Adult

KW - Olanzapine/adverse effects

KW - Antipsychotic Agents/adverse effects

KW - Benzodiazepines/adverse effects

KW - Schizophrenia/drug therapy

KW - Delayed-Action Preparations/adverse effects

KW - Syndrome

KW - Delirium/chemically induced

KW - Injections, Intramuscular

M3 - Tidsskriftartikel

C2 - 37170738

VL - 185

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 19

M1 - V02230069

ER -

ID: 346463893